Raymond James & Associates Bei Gene, Ltd. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Raymond James & Associates holds 14,250 shares of BGNE stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,250

Previous 21,275 33.02%

Holding current value

$2.52 Million

Previous $3.04 Million 5.4%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$143.93 - $224.51 $1.01 Million - $1.58 Million	-7,025 Reduced 33.02%	14,250 $3.2 Million
Q2 2024 Jul 19, 2024	BUY	$129.52 - $174.32 $9,843 - $13,248	76 Added 0.36%	21,275 $3.04 Million
Q1 2024 Apr 22, 2024	BUY	$141.8 - $181.47 $1.22 Million - $1.56 Million	8,602 Added 68.29%	21,199 $3.32 Million
Q4 2023 Jan 16, 2024	SELL	$158.67 - $201.58 $75,844 - $96,355	-478 Reduced 3.66%	12,597 $2.27 Million
Q3 2023 Oct 24, 2023	SELL	$179.87 - $225.13 $507,413 - $635,091	-2,821 Reduced 17.75%	13,075 $2.35 Million
Q2 2023 Jul 25, 2023	SELL	$178.3 - $266.78 $227,689 - $340,678	-1,277 Reduced 7.44%	15,896 $2.83 Million
Q1 2023 Apr 14, 2023	BUY	$215.53 - $274.5 $517,703 - $659,349	2,402 Added 16.26%	17,173 $3.7 Million
Q4 2022 Feb 08, 2023	BUY	$125.51 - $229.3 $22,089 - $40,356	176 Added 1.21%	14,771 $3.25 Million
Q3 2022 Oct 25, 2022	SELL	$131.8 - $202.24 $56,015 - $85,952	-425 Reduced 2.83%	14,595 $1.97 Million
Q2 2022 Aug 12, 2022	SELL	$121.11 - $216.05 $30,640 - $54,660	-253 Reduced 1.66%	15,020 $2.43 Million
Q1 2022 May 11, 2022	BUY	$146.52 - $269.56 $446,446 - $821,349	3,047 Added 24.92%	15,273 $2.88 Million
Q4 2021 Feb 08, 2022	BUY	$248.56 - $389.34 $75,562 - $118,359	304 Added 2.55%	12,226 $3.31 Million
Q3 2021 Nov 02, 2021	BUY	$249.6 - $403.14 $314,246 - $507,553	1,259 Added 11.81%	11,922 $4.33 Million
Q2 2021 Aug 11, 2021	BUY	$292.75 - $367.01 $1.77 Million - $2.22 Million	6,046 Added 130.95%	10,663 $3.66 Million
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $278,102 - $407,722	1,067 Added 30.06%	4,617 $1.61 Million
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $486,439 - $695,908	-2,198 Reduced 38.24%	3,550 $917,000
Q3 2020 Nov 04, 2020	BUY	$189.18 - $286.44 $670,832 - $1.02 Million	3,546 Added 161.04%	5,748 $1.65 Million
Q2 2020 Jul 28, 2020	BUY	$123.9 - $195.41 $272,827 - $430,292	2,202 New	2,202 $415,000
Q1 2020 Apr 21, 2020	SELL	$121.84 - $173.19 $206,153 - $293,037	-1,692 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$115.78 - $208.34 $195,899 - $352,511	1,692 New	1,692 $280,000
Q1 2019 May 06, 2019	SELL	$122.82 - $151.83 $374,601 - $463,081	-3,050 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$107.01 - $175.15 $50,936 - $83,371	476 Added 18.49%	3,050 $428,000
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $392,843 - $488,184	2,574 New	2,574 $443,000
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $233,172 - $331,441	-1,529 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$97.41 - $177.22 $148,939 - $270,969	1,529 New	1,529 $257,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Bei Gene, Ltd. Transaction History